Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Sangamo BioSciences, Inc. Snapshot | 6 | 1 |
| Sangamo BioSciences, Inc. Overview | 6 | 1 |
| Key Information | 6 | 1 |
| Key Facts | 6 | 1 |
| Sangamo BioSciences, Inc. Research and Development Overview | 7 | 3 |
| Key Therapeutic Areas | 7 | 3 |
| Sangamo BioSciences, Inc. Pipeline Review | 10 | 2 |
| Pipeline Products by Stage of Development | 10 | 1 |
| Pipeline Products Monotherapy | 11 | 1 |
| Sangamo BioSciences, Inc. Pipeline Products Glance | 12 | 5 |
| Sangamo BioSciences, Inc. Clinical Stage Pipeline Products | 12 | 1 |
| Phase II Products/Combination Treatment Modalities | 12 | 1 |
| Phase I Products/Combination Treatment Modalities | 13 | 1 |
| Sangamo BioSciences, Inc. Early Stage Pipeline Products | 14 | 1 |
| IND/CTA Filed Products/Combination Treatment Modalities | 14 | 1 |
| Preclinical Products/Combination Treatment Modalities | 15 | 1 |
| Discovery Products/Combination Treatment Modalities | 16 | 1 |
| Sangamo BioSciences, Inc. Drug Profiles | 17 | 17 |
| SB-728T | 17 | 1 |
| Product Description | 17 | 1 |
| Mechanism of Action | 17 | 1 |
| R&D Progress | 17 | 2 |
| SB-728HSPC | 19 | 1 |
| Product Description | 19 | 1 |
| Mechanism of Action | 19 | 1 |
| R&D Progress | 19 | 1 |
| SB-FIX | 20 | 1 |
| Product Description | 20 | 1 |
| Mechanism of Action | 20 | 1 |
| R&D Progress | 20 | 2 |
| SB-318 | 22 | 1 |
| Product Description | 22 | 1 |
| Mechanism of Action | 22 | 1 |
| R&D Progress | 22 | 1 |
| Stem Cell Therapy for Beta Thalassemia | 23 | 1 |
| Product Description | 23 | 1 |
| Mechanism of Action | 23 | 1 |
| R&D Progress | 23 | 1 |
| Gene Therapy for Sickle Cell Disease | 24 | 1 |
| Product Description | 24 | 1 |
| Mechanism of Action | 24 | 1 |
| R&D Progress | 24 | 1 |
| Gene Therapy for X-Linked SCID | 25 | 1 |
| Product Description | 25 | 1 |
| Mechanism of Action | 25 | 1 |
| R&D Progress | 25 | 1 |
| Gene Therapy to Activate Alpha-1 Antitrypsin for Alpha-Antitrypsin Deficiency | 26 | 1 |
| Product Description | 26 | 1 |
| Mechanism of Action | 26 | 1 |
| R&D Progress | 26 | 1 |
| Gene Therapy to Active Pulmonary Surfactant-Associated Protein B for Lung Diseases | 27 | 1 |
| Product Description | 27 | 1 |
| Mechanism of Action | 27 | 1 |
| R&D Progress | 27 | 1 |
| Gene Therapy to Inhibit Huntingtin Protein for Huntington s Disease | 28 | 1 |
| Product Description | 28 | 1 |
| Mechanism of Action | 28 | 1 |
| R&D Progress | 28 | 1 |
| SB-913 | 29 | 1 |
| Product Description | 29 | 1 |
| Mechanism of Action | 29 | 1 |
| R&D Progress | 29 | 1 |
| SB-FVIII | 30 | 1 |
| Product Description | 30 | 1 |
| Mechanism of Action | 30 | 1 |
| R&D Progress | 30 | 1 |
| SBLSD-3 | 31 | 1 |
| Product Description | 31 | 1 |
| Mechanism of Action | 31 | 1 |
| R&D Progress | 31 | 1 |
| SBLSD-4 | 32 | 1 |
| Product Description | 32 | 1 |
| Mechanism of Action | 32 | 1 |
| R&D Progress | 32 | 1 |
| Gene Therapy for Monogenic Diseases | 33 | 1 |
| Product Description | 33 | 1 |
| Mechanism of Action | 33 | 1 |
| R&D Progress | 33 | 1 |
| Sangamo BioSciences, Inc. Pipeline Analysis | 34 | 4 |
| Sangamo BioSciences, Inc. Pipeline Products by Target | 34 | 1 |
| Sangamo BioSciences, Inc. Pipeline Products by Route of Administration | 35 | 1 |
| Sangamo BioSciences, Inc. Pipeline Products by Molecule Type | 36 | 1 |
| Sangamo BioSciences, Inc. Pipeline Products by Mechanism of Action | 37 | 1 |
| Sangamo BioSciences, Inc. Recent Pipeline Updates | 38 | 11 |
| Sangamo BioSciences, Inc. Dormant Projects | 49 | 1 |
| Sangamo BioSciences, Inc. Discontinued Pipeline Products | 50 | 1 |
| Discontinued Pipeline Product Profiles | 50 | 1 |
| CERE-110 | 50 | 1 |
| CERE-120 | 50 | 1 |
| SB-509 | 50 | 1 |
| Sangamo BioSciences, Inc. Company Statement | 51 | 2 |
| Sangamo BioSciences, Inc. Locations And Subsidiaries | 53 | 1 |
| Head Office | 53 | 1 |
| Other Locations &Subsidiaries | 53 | 1 |
| Appendix | 54 | 2 |
| Methodology | 54 | 1 |
| Coverage | 54 | 1 |
| Secondary Research | 54 | 1 |
| Primary Research | 54 | 1 |
| Expert Panel Validation | 54 | 1 |
| Contact Us | 54 | 1 |
| Disclaimer | 55 | 1 |